Skip to navigation

Press Releases

MWC TSX: Quote: 0.235 | Change: -0.015 | 09.08.10 | 10:28:00 MST

BIOMS to Present at the BIO CEO and INVESTOR Conference

Edmonton, Alberta, February 8, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BIO CEO & Investor Conference 2008 in New York.

WHEN: Tuesday February 12th at 11:45 am (Eastern Time)

WHERE: Waldorf Astoria Hotel, New York

About BIO CEO & Investor Conference

The objective of the conference is to bring together institutional investors, industry analysts, and senior biotechnology executives in a neutral and collaborative forum to examine investment opportunities and issues affecting the industry. For more information visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Ryan Giese
VP Corporate Communications
Phone: 780-413-7152
rgiese@biomsmedical.com
Tony Hesby
Executive VP Corporate Affairs
Phone: 780-413-7152
thesby@biomsmedical.com
Amanda Stadel
Director Investor Relations
Phone: 780-413-7152
astadel@biomsmedical.com

 

Current News

?>